- Home
- Publications
- Publication Search
- Publication Details
Title
Association Between Antipsychotic Medication Use and Diabetes
Authors
Keywords
Antipsychotics, Diabetes, Weight gain, Insulin resistance, β-cell dysfunction
Journal
Current Diabetes Reports
Volume 19, Issue 10, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-03
DOI
10.1007/s11892-019-1220-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antipsychotic Use During Pregnancy and the Risk of Gestational Diabetes Mellitus
- (2019) Faruk Uguz JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes
- (2018) Yoonyoung Park et al. AMERICAN JOURNAL OF PSYCHIATRY
- Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
- (2018) Michael EJ Lean et al. LANCET
- Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability
- (2018) Davide Amato et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial
- (2018) Richard I. G. Holt et al. BRITISH JOURNAL OF PSYCHIATRY
- Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: A systematic review and meta-analysis
- (2017) John A. Naslund et al. GENERAL HOSPITAL PSYCHIATRY
- The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C
- (2017) Caleb C. Lord et al. JOURNAL OF CLINICAL INVESTIGATION
- Treatment of Diabetic Ketoacidosis Associated With Antipsychotic Medication
- (2017) Antonia Vuk et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Impaired Glucose Homeostasis in First-Episode Schizophrenia
- (2017) Toby Pillinger et al. JAMA Psychiatry
- Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder
- (2017) Julie R. Larsen et al. JAMA Psychiatry
- Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes
- (2017) Jiezhong Chen et al. Frontiers in Neuroscience
- Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis
- (2016) Varuni Asanka de Silva et al. BMC Psychiatry
- Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial
- (2016) Pelle L. Ishøy et al. DIABETES OBESITY & METABOLISM
- BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
- (2016) Stephen J Cooper et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports
- (2016) Christoffer Polcwiartek et al. PSYCHOPHARMACOLOGY
- The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity
- (2016) Helene Speyer et al. World Psychiatry
- Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis
- (2016) Davy Vancampfort et al. World Psychiatry
- Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics
- (2016) Britta Galling et al. JAMA Psychiatry
- The STRIDE Weight Loss and Lifestyle Intervention for Individuals Taking Antipsychotic Medications: A Randomized Trial
- (2015) Carla A. Green et al. AMERICAN JOURNAL OF PSYCHIATRY
- Serotonin in antipsychotic drugs action
- (2015) Davide Amato BEHAVIOURAL BRAIN RESEARCH
- Assessment and treatment of physical health problems among people with schizophrenia: national cross-sectional study
- (2014) Mike J. Crawford et al. BRITISH JOURNAL OF PSYCHIATRY
- A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes
- (2014) Farah Alghamdi et al. CELLULAR SIGNALLING
- A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults
- (2014) Leslie Citrome et al. CURRENT MEDICAL RESEARCH AND OPINION
- Diabetes mellitus and severe mental illness: mechanisms and clinical implications
- (2014) Richard I. G. Holt et al. Nature Reviews Endocrinology
- Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats
- (2014) Meng He et al. PSYCHONEUROENDOCRINOLOGY
- Antipsychotic Treatment and Mortality in Schizophrenia
- (2014) M. Torniainen et al. SCHIZOPHRENIA BULLETIN
- Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis
- (2014) Y. Mizuno et al. SCHIZOPHRENIA BULLETIN
- Atypical antipsychotics and hyperglycemic emergencies: Multicentre, retrospective cohort study of administrative data
- (2014) Lorraine L. Lipscombe et al. SCHIZOPHRENIA RESEARCH
- Effects of Antipsychotic Medications on Appetite, Weight, and Insulin Resistance
- (2013) Chao Deng ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness
- (2013) Gail L. Daumit et al. NEW ENGLAND JOURNAL OF MEDICINE
- A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls
- (2013) Davy Vancampfort et al. World Psychiatry
- Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat
- (2013) K J Davey et al. Translational Psychiatry
- Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials
- (2012) Jacqueline Caemmerer et al. SCHIZOPHRENIA RESEARCH
- Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?
- (2011) Marianne Ulcickas Yood et al. BMC Psychiatry
- Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder
- (2011) Leslie Citrome et al. CLINICAL DRUG INVESTIGATION
- Antipsychotic drugs suppress the AKT/NF-κB pathway and regulate the differentiation of T-cell subsets
- (2011) Mao-Liang Chen et al. IMMUNOLOGY LETTERS
- Clozapine impairs insulin action by up-regulating AKT phosphorylation and Ped/Pea-15 protein abundance
- (2011) Fabio Panariello et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Treatment with antipsychotics and the risk of diabetes in clinical practice
- (2010) Lars Vedel Kessing et al. BRITISH JOURNAL OF PSYCHIATRY
- Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients
- (2010) Jimmi Nielsen et al. NEUROPSYCHOPHARMACOLOGY
- Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
- (2010) Christine Rummel-Kluge et al. SCHIZOPHRENIA RESEARCH
- Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes
- (2009) E. H. Morrato et al. DIABETES CARE
- Obesity, serious mental illness and antipsychotic drugs
- (2009) Richard I. G. Holt et al. DIABETES OBESITY & METABOLISM
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)
- (2009) M. De Hert et al. EUROPEAN PSYCHIATRY
- Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity
- (2009) Grigori Joffe et al. JOURNAL OF CLINICAL PSYCHIATRY
- 30 Days of Continuous Olanzapine Infusion Determines Energy Imbalance, Glucose Intolerance, Insulin Resistance, and Dyslipidemia in Mice
- (2009) Roberto Coccurello et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
- (2009) Jari Tiihonen et al. LANCET
- The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study
- (2009) Marianne Ulcickas Yood et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- The story of antipsychotics: Past and present
- (2009) ChaitraT Ramachandraiah et al. Indian Journal of Psychiatry
- Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
- (2008) René S Kahn et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation